article thumbnail

ACSS2 gene variants determine kidney disease risk by controlling de novo lipogenesis in kidney tubules

Journal of Clinical Investigation - Cardiology

Worldwide, over 800 million people are affected by kidney disease, yet its pathogenesis remains elusive, hindering the development of novel therapeutics. Lipid accumulation and the expression of genes related to DNL were elevated in the kidneys of patients with fibrosis.

article thumbnail

Targeting de novo lipogenesis to mitigate kidney disease

Journal of Clinical Investigation - Cardiology

Ten percent of the population worldwide suffers from chronic kidney disease (CKD), but the mechanisms driving CKD pathology are incompletely understood. Identify acyl-CoA synthetase short-chain family 2 (ACSS2) as a disease risk gene and demonstrate a role for ACSS2 in de novo lipogenesis (DNL).

article thumbnail

Characterisation of the octogenarians presenting to the diagnostic heart failure clinic: SHEAF registry

Open Heart

We aimed to determine the clinical characteristics which were associated with optimisation of HF pharmacological intervention in the clinic, conducting multivariate regression analysis. Frailty, chronic kidney disease and ischaemic heart disease increased significantly versus the first period (p<0.001).

article thumbnail

Targeting pharmacotherapies for inflammatory and cardiorenal endpoints in kidney disease

Journal of Cardiovascular Pharmacology

Inflammation is an important contributor to excess cardiovascular risk and progressive renal injury in people with CKD.

article thumbnail

Abstract 4141474: Impact of Serum 5-Hydroxytryptophan Levels on Coronary Artery Calcification Severity in Acute Coronary Syndrome Patients: Insights from the Microbiota-Gut-Brain Axis

Circulation

While it is known to increase serotonin levels in the brain and gastrointestinal tract, its pharmacology remains largely unexplored. However, the role of 5-HTP in vascular disease is not well understood. to 2.31); chronic kidney disease 1.07 (0.33 95% CI = 2.6 to 40686.5). to 1.77); dyslipidemia 0.91 (0.5

article thumbnail

A mechanism for the treatment of cardiovascular and renal disease

Journal of Cardiovascular Pharmacology

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. CVD and kidney disease are closely related, with kidney injury increasing CVD mortality. CVD and kidney disease are closely related, with kidney injury increasing CVD mortality.

article thumbnail

Comparative Analysis of Anticoagulation Versus Combination Anticoagulation and Antiplatelet Therapy in Atrial Fibrillation Patients Presenting With Gastrointestinal Bleeding

Journal of Cardiovascular Pharmacology

Cox regression analysis revealed chronic kidney disease (CKD) (hazard ratio (HR) 2.05, 95% confidence interval (CI) [1.04,4.05] (p= 0.038)] and warfarin use [(HR 4.94, 95% CI [1.11,22.09] (p= 0.037)] to be independent predictors of mortality at 12 months.